ClinVar Miner

Submissions for variant NM_004113.6(FGF12):c.14-47649A>G

dbSNP: rs2108776132
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
New York Genome Center RCV002227677 SCV002506750 uncertain significance Developmental and epileptic encephalopathy, 47 2021-05-14 criteria provided, single submitter clinical testing The c.37A>G (p.Lys13Glu) variant identified in the FGF12 gene substitutes a well conserved Lysine for Glutamic Acid at amino acid 13/244 (exon 1/5). This variant is absent from gnomAD(v3.1.1) suggesting it is not a common benign variant in the populations represented in that database. In silico algorithms do not agree on the effect of this variant, as it is predicted both Damaging (SIFT; score:0.002) and Benign (REVEL; score:0.517) to the function of the canonical transcript. This variant is absent from ClinVar and to our current knowledge has not been reported in affected individuals in the literature. The p.Lys13 residue is within the Bipartite nuclear localization signal of FGF12 (UniProtKB:P61328). Given the lack of compelling evidence for its pathogenicity, the c.37A>G (p.Lys13Glu) variant identified in the FGF12 gene is reported as a Variant of Uncertain Significance.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.